Risk of development of drug resistance in patients starting antiretroviral therapy with three or more drugs in routine clinical practice. 13th International Drug Resistance Workshop, 8-12 June 2004.. 2004.
Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: the effect of a nucleoside backbone. Antivir Ther. 18:213-9.. 2013.
Significant HIV-1 subtype differences observed in the development of accessory mutations associated with high-level resistance to reverse transcriptase inhibitors. International Workshop on HIV & Hepatitis Virus Resistance and Curative Strategies, 5-9 June 2012. Antiviral Therapy 17 Suppl 1:A84.. 2012.
Source of HIV-1 drug-resistant minority variants in people who are recently infected. 24th International HIV Dynamics and Evolution.. 2017.
Subtype-specific differences in the development of accessory mutations associated with high-level resistance to HIV-1 nucleoside reverse transcriptase inhibitors. J Antimicrob Chemother. 68:1220-36.. 2013.
Sustained Spread of HIV-1 Drug Resistance in Treatment-Naïve Patients in the United Kingdom. Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014.. 2014.
Temporal patterns in the rate of transmitted resistance in the UK. 9th European AIDS Conference, 25-29 October 2003.. 2003.
Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ. 345:e5253.. 2012.
Time trends in HIV drug resistance in ART-experienced patients in the UK: impact of improved treatments and boosted protease inhibitors. 13th Annual Conference of the British HIV Association, 25-28 April 2007.. 2007.
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ. 331:1368.. 2005.
Transmission and persistence of antiretroviral resistance amongst drug naïve HIV positive individuals in the United Kingdom. International Workshop on Antiviral Drug Resistance, June 2014.. 2014.
Transmission dynamics of CRF50_A1D across most at risk communities in the UK. 19th International HIV Dynamics & Evolution Conference, 25-28 April 2012.. 2012.
Transmission network parameters estimated from HIV sequences for a nationwide epidemic. J Infect Dis. 204:1463-9.. 2011.
Transmission of Non-B HIV Subtypes in the United Kingdom Is Increasingly Driven by Large Non-Heterosexual Transmission Clusters. J Infect Dis. 213:1410-8.. 2016.
Trends in transmitted drug resistance to HIV-1 in the UK since 2010. British HIV Association Conference (BHIVA) 2015.. 2015.
Trends in transmitted HIV drug resistance among non-B subtypes in the UK. Ninth International Congress on Drug Therapy in HIV Infection, 9-13 November 2008.. 2008.
UK HIV drug resistance database: background and recent outputs. J HIV Ther. 12:97-8.. 2007.
The UK HIV Drug Resistance Database: development and use for national surveillance. 12th International HIV Drug Resistance Workshop, 10-14 June 2003.. 2003.
Use of emtricitabine or lamivudine following detection of the M184V/I HIV-1 resistance mutation. 23rd International Workshop on HIV and Hepatitis Observational Databases.. 2019.